Dr James Poindexter
ATLANTA, July 27, 2023 (Newswire.com)
–
American Medical Administrators, Inc., (American Medical), a new and innovative healthcare …
The post American Medical Administrators, Inc. Announces Doctor James Poindexter Joining the Organization and the Acquisition of Georgia Vascular Specialists, PC. first appeared on Enrose Magazine.
Company Expands Mask Product Line Approved for Medical Settings
MOUNT VERNON, N.Y., July 27, 2023 (Newswire.com)
…
The post Bona Fide Masks Corp. Inks Exclusive U.S. Distribution Agreement With Harley Commodity for NIOSH- and FDA-Approved Surgical N95 Masks first appeared on Enrose Magazine.
Resiliently Sharp Line of Scalers and Curettes
rezSHARP Launch Photo rezSHARP line of Scalers and Curettes by TBS Dental
…
The post TBS Dental Introduces Revolutionary rezSHARP Hygiene Instrument Line first appeared on Enrose Magazine.
Doug Morse-Schindler of HealthJoy Honored for Driving the Adoption of Virtual Care through Bold Leadership and an Unwavering Commitment to Excellence
…
The post HealthJoy Leader Wins Teladoc Health Forum Transformational Leadership Award first appeared on Enrose Magazine.
Sendero Managing Director Jeff Schar
DALLAS, July 26, 2023 (Newswire.com)
–
Sendero, a management consulting firm with expertise delivering strategic p…
The post Sendero Managing Director Jeff Schar Elected to the Tennessee Chapter of HIMSS Board of Directors first appeared on Enrose Magazine.
A groundbreaking case report publication on the impact of rapid molecular testing on lung cancer patients
TEL AVIV, Israel, July 26, 2023 (Newswire.com)
–
Imagene, an emerging leader in AI-based precision oncology, is pleased to announce the publication of a case report in the Journal of Clinical Pathology. The report, titled “Artificial Intelligence (AI) Molecular Analysis Tool Assists in Rapid Treatment Decision in Lung Cancer” demonstrates the successful application of Imagene’s AI technology in rapid molecular testing for lung cancer patients, conducted as part of a joint prospective study with the Pathology Department at the Sourasky Medical Center.
The case report describes two patients in their early 40s who were admitted at the emergency room with severe headaches. Brain MRIs and CT scans revealed suspected metastatic lung cancer that was confirmed by a biopsy analysis at the pathology lab. The patients needed immediate intervention and could not afford to wait for comprehensive genomic profiling results. To allow prompt decisions without compromising the small amount of remaining tissue, Imagene’s rapid AI-based molecular testing was used as part of collaborative research.
Prof. Dov Hershkovitz, Head of the Pathology Department at the Sourasky Medical Center, said, “The ability to use Imagene’s AI technology in these cases was a game-changer. It allowed us to bypass the usual lengthy waiting period associated with comprehensive genomic profiling. This technology is revolutionizing the way we diagnose patients, with the potential to improve outcomes and save lives.”
The Imagene algorithmic inference identified, within minutes, positive EGFR mutation, from the biopsy H&E image. A subsequent rapid RT-PCR test for EGFR mutations was indeed positive, allowing for immediate targeted treatment initiation and avoiding the need for whole brain radiation therapy. Both patients’ MRI scans after two months showed significant improvement with disappearance of the enhancement. A news channel also featured this case, including an interview with the patient. She shared her personal experience and highlighted the significant positive psychological impact that the rapid testing had on her.
“These real-life cases underscore the transformative potential of AI in precision oncology,” said Dean Bitan, Co-founder and CEO of Imagene. “Our technology enabled the medical team to make a rapid, informed treatment decision, ultimately saving precious time and improving the patient’s prognosis. We are proud to be at the forefront of this revolution, working hand-in-hand with leading medical centers on prospective studies to enhance patient care and impact patients’ lives.”
“One of the hardest things as an oncologist is to tell my patients we need to wait for a molecular diagnosis in order to start the optimal personalized treatment. It is groundbreaking to be able to have a molecular profile from the biopsy image within minutes,” added Prof. Ido Wolf, Head of Oncology, Sourasky Medical Center. “With the help of the rapid AI-based diagnoses, we are able to navigate patients’ journeys and make immediate informed treatment decisions that have such a great impact on our patients’ lives.”
Imagene continues to pursue the advancement of AI in precision oncology, providing innovative solutions that enhance cancer patients’ care and streamline clinical workflows. This technology can make molecular testing accessible to all cancer patients, particularly those in under-tested populations.
About Imagene
Imagene is an emerging leader in AI-based precision oncology. The company leverages AI to profile, within minutes, a broad range of cancer biomarkers from a digitized biopsy image alone, providing physicians with immediate oncology intelligence to ensure optimal treatment for all cancer patients. Imagene’s multidisciplinary team of data scientists, biologists, software engineers, and medical experts is committed to scientific excellence and collaboration, advancing precision oncology, and improving patient outcomes.
For more information, please visit imagene-ai.com.
Contact Information:
Avital Rabani
Head of Marketing
Original Source:
Imagene’s AI-Based Molecular Profiling Revolutionizes Lung Cancer Diagnostics: Two Patients Receive Immediate Targeted Therapy, Avert Brain Radiation
The post Imagene’s AI-Based Molecular Profiling Revolutionizes Lung Cancer Diagnostics: Two Patients Receive Immediate Targeted Therapy, Avert Brain Radiation first appeared on Enrose Magazine.
Happy Head’s™ Dermatologists Have Developed a First-of-Its-Kind Hair Growth Formula With Latanoprost, Finasteride and Minoxidil
LOS ANGELES, July 25, 2023 (Newswire.com)
–
Happy Head™ today announces the launch of its newest innovation, a topical hair growth formula with latanoprost. Designed by board-certified dermatologists and hair restoration experts, this revolutionary formula combines the strongest hair growth medications on the market. The exclusive offering is the first of its kind to infuse clinically proven latanoprost with powerful hair growth ingredients finasteride and minoxidil.
“At Happy Head™, we’re always looking for innovative ways to solve hair loss. Latanoprost is a successful hair growth ingredient you’ll find in products like Latisse for eyelash growth. To improve the results of latanoprost for scalp growth, we’ve combined 0.005% latanoprost with 8.0% minoxidil and 0.3% finasteride. This new topical solution is a great option for those who haven’t seen success with other active ingredients,” said Dr. Ben Behnam, M.D., FAAD, and co-founder of Happy Head™.
Happy Head’s™ new latanoprost formula will expand the company’s product offering for a new hair growth option. Latanoprost enhances the growth phase of hair follicles, especially when combined with the strongest hair growth medicines on the market — finasteride and minoxidil. Dermatologists say three to six months of daily topical latanoprost, finasteride, and minoxidil use will not only help regrow lost hair, but also prevent further hair loss.
Previously, latanoprost was only used for eyelash growth products and not widely available for scalp regrowth treatment. But a new study showed that latanoprost increased hair density in as little as 24 weeks. Happy Head’s™ dermatologists have cracked the code to unlock the potential of topical latanoprost for millions of customers looking for a clinically proven growth alternative.
Hair loss is a huge problem that can cause intense psychological distress. Over two-thirds of men will experience hair loss by the age of 35, but it’s not just men who are dealing with this problem. Over 40 percent of Americans who experience hair loss are women.
Because hair loss affects so many people, this combination of ingredients in one convenient topical formula will provide customers with an even more powerful, clinically proven treatment with a lower risk of side effects. Happy Head™ is gearing up for several exclusive product launches this year that will continue to solidify its leadership in the telemedicine space.
About Happy Head™
Happy Head™ is a telemedicine provider of dermatologist-prescribed, customized hair growth medicine and treatments. Founded in 2021, Happy Head™ specializes in customized formulas to prevent and treat hair loss in both men and women. Happy Head’s™ products are backed by some of the best dermatologists and hair restoration experts in the industry. The company hopes to help people who struggle with hair loss to not only regrow their hair, but also regain their confidence and sense of self often caused by hair loss.
Contact Information:
Carolina Calkins
PR Manager
Original Source:
Happy Head Launches New Topical Formula Containing Latanoprost for Hair Growth
The post Happy Head Launches New Topical Formula Containing Latanoprost for Hair Growth first appeared on Enrose Magazine.
AI-Driven Care Gap Program Has Delivered $45 Million in Revenue Since Launch
Get Well Get Well provides enterprise patient engagement and navigat…
The post Get Well Announces Program Results With Adventist Health: Nearly One Million Consumers Back to Care first appeared on Enrose Magazine.
Fortifeye Vitamins Introduces Next Gen Zinc-Free Macular Defense
Zinc Free Macular Defense Fortifeye Next Gen Zinc Free Macular Defense
…
The post Fortifeye Vitamins Breaks New Ground With Next Gen Zinc-Free Macular Degeneration Formula first appeared on Enrose Magazine.
Investigational young Fresh Frozen Plasma (yFFP®) Treatments Study YP042022 IRCM-2022-333
HOUSTON, July 25, 2023 (Newswire.com)
–
Golden Gift, a 501(c)(3) nonprofit organization in support of the therapeutic use of blood plasma from young donors in treating age-related conditions, has shared an early announcement of significantly beneficial clinical trial evidence for Fresh Frozen Plasma (yFFP) Treatments. Chronic conditions developing in our aging population are now currently accounting for 90% of the United States’ health care costs. A frightening fact for the youth of our country is that health care expenses for these patients are expected to reach $5 trillion by 2025. Who will pay for it? Band-aid medication is not the answer. In fact, the greatest risk factor for disease is the degeneration of the body that develops as we age. The real resolution of age-associated diseases arises from insights into understanding and supporting the fundamental biology of age changes.
All animate and inanimate matter have the same universal molecular etiology. The science of physics indicates that genes do not drive the aging process, but the general loss of molecular organization does. Every organ and blood vessel in our body as we undergo our basic metabolism, replacement, and repair, experiences a movement towards spreading out or loss of energy. For example, hot coffee gets cold, balls roll down hill and 3-dimensional complex molecules cannot be created with accuracy indefinitely. Therefore, large organs and metabolic functions fail, and can no longer support the existence of the organism.
Age changes occur in every multicellular animal. As the system starts to lose the ability to create complex matricellular proteins, non-structural proteins that support cell function, it begins losing the ability to ‘run the system’ – your body. Longevity is determined by the ability to maintain the potential energetics of all molecules.
How long can one continue to make the necessary complex structures as the laws of physics work to break us down? Waves of changes in the dysfunctional proteome of the blood in the fourth, seventh, and eighth decades of life reflect this degeneration: https://pubmed.ncbi.nlm.nih.gov/31806903. As less optimal complex usable proteins begin to circulate through the blood stream, the body becomes less efficient and as a result, we age, and we get sick: https://pubmed.ncbi.nlm.nih.gov/31932806.
The removal of old cells and other debris, such as through the apheresis process, may in-fact, slow degeneration, and create some immune modulation, and cell stimulation. Everyone can use modalities of calorie restriction, exercise, and supplements to enhance the functions of their cells. However due to the Second Law of Thermodynamics, eventually complex molecules within the milieu cannot be produced any longer and must be replaced:
https://nyaspubs.onlinelibrary.wiley.com/doi/abs/10.1196/annals.1395.001
Young blood plasma, collected from sex-identified individuals between the ages of 18 – 25, reverses age-related profiles and initiates systemic rejuvenation by introducing 10K proteins, 5K peptides, 45 cytokines, 50 sex matched hormones and 1.84 billion exosomes per ml, along with minerals and gut microbiota metabolites from healthy volunteer donors at the peak of their reproductive maturity. What your body can no longer make, you can replace and really slow the aging process, enhance fitness, and ward off disease.
This concept is illustrated in patients with cardiac disease. Those with heart failure will produce higher levels of BNP (brain natriuretic peptide) due to the stress on the muscle and overall cardiac function. A 79-year-old male had his BNP drop from over 1,300 pg/ml to 705 pg/ml after a 2-liter exchange, and a 71-year-old male with severe heart failure saw his BNP drop from 6,800 pg/ml to 715 pg/ml with 1-liter of his old plasma out, and 3-liters from young donors in, over two days.
Aging is now understood as a gradual, progressive deterioration simultaneously affecting different organ systems. Those with a faster ‘Pace of Aging’ tend to experience more rapid aging-related declines in physical and cognitive functions, have a higher predisposition to disease, and an accelerated time to death. We call these epigenetic changes. “Genetics loads the gun, but environment shoots it.”
Evidence suggests that interventions to slow Pace of Aging will slow the progression to disease development and works to extend health/life span. The DunedinPACE is a highly accurate and reliable single-time-point measure of methylation that quantifies an individual’s Pace of Aging by evaluating their present state health to different biological processes of a population that was followed for age changing markers over time.
Epigenetic changes that slow aging are difficult to realize and maintain. Prolonged significant calorie restriction was shown to reduce DunedinPACE by only 2-3% after two years: https://doi.org/10.1038/s43587-022-00357-y. Clearly, an overall healthy exercise plan as part of anyone’s lifestyle has also been proven to reduce the rate of aging. However, due to the laws of physics, interventions without adding young molecules only work to a point.
A DunedinPACE of 1 was established to reference an average rate of 1 year of biological aging per year of chronological aging. Among Dunedin Study participants, the range of values extends from just above 0.6 (indicating an aging rate nearly 40 percent slower than the norm) to nearly 1.4 (indicating an aging rate 40 percent faster than the norm).
Sensitive to all interventions, the DunedinPACE very importantly allows testing of treatments intended to extend health span and lifespan in humans. For example, a 67-year-old male participating in our study with Parkinson’s disease received 2.5-liters of young Fresh Frozen Plasma (yFFP) through three exchanges within thirty days. In four months, his DunedinPACE was reduced by 18% to 0.82.
A similarly significant outcome was realized in four months by a 78-year-old female with a family history and personal signs of dementia. She received 1.8-liters of young plasma in two-infusions, reducing her DunedinPACE by 17% to 0.78.
Making an early announcement of significantly beneficial clinical trial documentation from an ongoing study is important from many viewpoints: clinicians practicing evidence-based medicine; future patients to whom the studies apply; patients currently participating in clinical trials; and scientists, investigators, and regulators who strive to balance continuing studies with disseminating data in confirmation of therapeutic advances as quickly as is reasonable.
Our Investigational young Fresh Frozen Plasma (yFFP) Treatments Study continues to treat patients in the major cities in Texas by more than a dozen IRB-registered Co-Investigators. Additional outcomes will be presented at RAADfest in September and at the A4M World Congress in December.
https://www.youngplasmastudy.com
https://www.youtube.com/@dianginsbergmd-optimalhealth
All research in the United States involving human subjects must be reviewed by an Institutional Review Board (IRB), unless specifically exempted by a federal regulation. Review boards protect the rights, privacy, and health of the research subjects in determining research will be conducted in a safe and ethical manner.
The Institute of Regenerative and Cellular Medicine
Barbara Krutchkoff, PhD., Executive Director
[email protected] / Phone: (888) 664-8893
IRB Registration Number: IRB00009500
IRB Parent/Organization Number: IORG0007913
Contact Information:
Dian Ginsberg, MD
Principle Investigator
(281) 569-4289
Related Files
Golden Gift Parkinson’s Disease study.pdf
Ginsberg YP042022v2 9.31.22 Approval.pdf
Original Source:
Early Announcement of Significantly Beneficial Clinical Trial Evidence From Young Blood Plasma Treatments
The post Early Announcement of Significantly Beneficial Clinical Trial Evidence From Young Blood Plasma Treatments first appeared on Enrose Magazine.
